Tuberculosis-specific antigen stimulated and unstimulated interferon-γ for tuberculous meningitis diagnosis: A systematic review and meta-analysis

Fangyu Shi¹, Xia Qiu², Mingjing Yu³, Yan Huang¹ *

¹ Department of Health Management Center, West China Hospital, Sichuan University, Chengdu, China, ² Department of Pediatrics, West China Second University Hospital, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China, ³ Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

* huangyan_0819@163.com

Abstract

Objective

Tuberculous meningitis (TBM) is one of the most devastating TB. Accurate identification of TBM is helpful to eliminate TB. Therefore, we assessed the performance of TBAg stimulated IFN-γ (IGRA) and unstimulated IFN-γ in blood and cerebrospinal fluid (CSF) for diagnosing TBM.

Methods

We searched Web of Science, PubMed, Embase and the Cochrane Library databases until March 2022. Bivariate and hierarchical summary receiver operating characteristic models were employed to compute summary estimates for diagnostic accuracy parameters of IGRA and unstimulated IFN-γ in blood and cerebrospinal fluid (CSF) for diagnosing TBM.

Results

28 studies including 1,978 participants and 2,641 samples met the inclusion criteria. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUROC) of blood IGRA were separately as 0.73, 0.83, 4.32, 0.33, 13.22 and 0.86, indicating a good diagnostic accuracy of blood IGRA for detecting TBM. The summary sensitivity, specificity, PLR, NLR, DOR and AUROC of CSF IGRA were separately as 0.77, 0.91, 8.82, 0.25, 34.59 and 0.93, indicating good diagnostic accuracy of CSF IGRA for detecting TBM. The summary sensitivity, specificity, PLR, NLR, DOR and AUROC of CSF IFN-γ were separately as 0.86, 0.92, 10.27, 0.16, 65.26 and 0.95, suggesting CSF IFN-γ provided excellent accuracy for diagnosing TBM.
Conclusions

For differentiating TBM from non-TBM individuals, blood and CSF IGRA are good assays and unstimulated CSF IFN-γ is an auxiliary excellent marker.

Introduction

Tuberculosis (TB) is one of the oldest infectious diseases and continues to threaten millions of citizens, especially in high-burden TB countries [1]. According to the 2020 global TB report, the World Health Organization (WHO) estimated that TB affected between 8.9 to 11.0 million individuals worldwide in 2019 [1]. Tuberculous meningitis (TBM) is one of the most devastating presentations of TB, with approximately 100,000 TBM cases reported annually [2, 3]. The nonspecific clinical features and delay in antitubercular therapy of TBM are responsible for neurological sequelae, seizures, and hydrocephalus, or even death in approximately 50% of patients [4, 5].

In defect of specific clinical symptoms and definite laboratory tests, early TBM diagnosis can be challenging. The composite diagnostic criteria of TBM include the examination of the presence of mycobacterium in the cerebrospinal fluid (CSF), histopathological, clinical, radiographical, and laboratory features [6]. Mycobacterial culture is the reference standard for the diagnosis of TBM, but its turn-around time of 6–8 weeks represents a significant limitation [5, 7]. Acid-fast bacilli (AFB) microscopy of stained CSF samples is the most widely used, rapid, and cost-effective diagnostic method; however, it has a poor sensitivity (10–15%) [8, 9]. Nucleic acid amplification tests (NAATs) are potential methods for TBM diagnosis, but they also have relatively low sensitivities (64% against CSF mycobacterial culture and 68% against a composite reference standard) [10, 11]. The CSF Xpert MTB/RIF test can rapidly differentiate TBM, with variable performance (sensitivity: 50–60%) and cost effectiveness [12]. Brain computed tomography (CT) and magnetic resonance imaging (MRI) are part of the clinical assessment of TBM, but they have limited clinical utility for early stage [4, 13]. Additionally, adenosine deaminase (ADA), the most commonly used laboratory parameter for TBM, has limited utility, especially in patients co-infected with the human immunodeficiency virus (HIV) [14]. Considering the limitations of the currently available methods, additional diagnostic assays for TBM are urgently needed.

Interferon-γ (IFN-γ) is a cytokine mainly produced and released by activated immune cells after *Mycobacterium tuberculosis* infection [15, 16]. Moreover, IFN-γ is increased in the CSF of patients with TB [17, 18]. IFN-γ includes *M. tuberculosis*-specific antigen (TBAg, like early secretary antigenic target 6, culture filtrate protein 10, etc) stimulated form and unstimulated form. Interferon-gamma release assay (IGRA), which is a TBAg-stimulated form of IFN-γ, detects the IFN-γ response of effector T cells to TBAg stimulation [3, 5]. Currently, IGRA can be performed by two approaches: QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB. In 2016, a meta-analysis of TBM yielded a summary sensitivity of 0.78 and specificity of 0.61 for blood IGRA, and a pooled sensitivity of 0.77 and specificity of 0.83 for CSF IGRA [19]. However, we found two studies that combined other central nervous system (CNS) TB (for example, intracranial tuberculoma) data along with the TBM data [20, 21]. In this study, we conducted a systematic review and meta-analysis to assess the diagnostic performance of TBAg-stimulated and unstimulated IFN-γ in blood and CSF for detecting patients with TBM.
Materials and methods

Search strategy

Our team followed the 2018 guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Diagnostic Test Accuracy (PRISMA-DTA) statement published by McInnes et al [22]. This protocol was published on PROSPERO (CRD42021269819). We screened published reports stored in the Web of Science, PubMed, Embase, and the Cochrane Library databases since the inception of English citations indexed up to March 10, 2022. The following search terms were used: (tuberculous meningitis OR tuberculosis meningitis OR tubercular meningitis OR TBM OR meningeal tuberculosis OR extrapulmonary tuberculosis OR EPTB) AND (interferon OR IFN OR interferon-gamma OR gamma-interferon OR interferon-γ OR IFN-gamma OR IFN-γ OR interferon-gamma release assay OR IGRA OR QuantiFERON-TB OR QFT OR T-SPOT.TB). Furthermore, we reviewed the bibliographies of relevant articles to identify additional potential studies. An agreement of the Institutional Ethics Committee was not required because only publicly available reports were included in the analysis.

Study selection

We selected original studies reporting IFN-γ for diagnosing TBM patients from non-TBM controls using the following criteria: (a) participants including TBM patients and non-TBM controls; (b) index test including two forms of IFN-γ, as TBAg-stimulated IFN-γ (IGRA, including QFT-GIT and T-SPOT.TB; TBAg, including early secretary antigenic target 6 and culture filtrate protein 10) and unstimulated IFN-γ in blood and CSF; (c) diagnostic standard for TBM including microbiologic in CSF (positivity of M. tuberculosis culture or NAAT or polymerase chain reaction, existence of AFB), histopathologic (presence of caseating granuloma in meninges), clinical, radiographic, and laboratory features (adequate resolution of hydrocephalus, granulomas, or basal exudates after empiric antitubercular therapy) [6]; (d) outcomes including sensitivity and specificity of IFN-γ, as well as those where the numerical data computed both these measures; (e) study designs, including randomized controlled trials and prospectively/retrospectively observational trials (cohort and cross-sectional studies). A publication including the largest participant samples was selected from among the identified articles reporting results on overlapping datasets. The optimal cutoff was selected among the articles reporting two or more diagnostic thresholds. The composite definition of the gold standard was adopted, which enrolled definite and probable TBM subjects.

We excluded all studies that were duplicated, non-English and animal publications, editorials and reviews, case reports, abstracts, biochemical and descriptive studies, studies without a control group, and articles presenting original data of less than five participants. Two investigators independently reviewed the titles and abstracts of the citations and full-text of potential studies to ensure that the inclusion criteria were fulfilled. Any disagreements were resolved by consensus.

Data extraction and quality assessment

Two investigators independently extracted the following data from the eligible articles: first author name, date of publication, country where the study was conducted, TB burden, study design, number of participants (TBM/non-TBM individuals), diagnostic reference standard of TBM, and index test including the forms of assay (IGRA or unstimulated IFN-γ), method, cut-off, and TBAg-stimulated condition. In addition, according to different forms of IFN-γ (blood IGRA, CSF IGRA, unstimulated blood IFN-γ, and unstimulated CSF IFN-γ), blood and CSF
samples, sensitivity, specificity, true positive (TP), false positive (FP), false negative (FN), and true negative (TN) data were extracted. The Quality Assessment of Diagnostic Accuracy Studies tool-2 (QUADAS-2), recommended by the Cochrane Collaboration, was used to summarize the methodological quality of the selected studies [23]. Deviations were resolved through consensus. The RevMan software (version 5.3; Cochrane, London, UK) was used to generate the figure of quality assessment.

**Statistical analysis**

A bivariate random model was used to calculate the summary sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) estimates for the different forms of IFN-γ, with 95% confidence intervals (CIs), as we expected significant heterogeneity in eligible studies. Furthermore, the area under the summary receiver operating characteristic curve (AUROC) was calculated. In general, AUROC below 0.75, between 0.75 and 0.93, or exceeding 0.93, indicated that the diagnostic accuracy of IFN-γ was not accurate, good, or excellent, respectively [24]. A hierarchical summary receiver operating characteristic (HSROC) model was constructed to summarize the overall diagnostic accuracy of IFN-γ [25]. We graphically identified the differences in the diagnostic performance across eligible studies using the HSROC curve.

$I^2$ statistics was used to judge heterogeneity, with $I^2 > 0.75$ indicating high heterogeneity [26]. The potential causes of heterogeneity were investigated using meta-regression and subgroup analyses. Subgroups were defined as different forms of TBAg-stimulated IFN-γ (T-SPOT.TB and QFT-GIT). Deeks’ funnel plot was used to graphically evaluate publication bias, in which $P < 0.10$ showed substantial asymmetry, suggesting the existence of bias [27]. All data were analyzed using the Stata software (version 14.0; StataCorp, College Station, TX, USA).

**Results**

**Characteristics of the included articles**

We identified 1053 records across four electronic databases and 2 records from bibliographies of relevant articles, among which 362 duplicated records were excluded. Following an initial screening of titles and abstracts, we excluded 628 records, of which 353 records were not eligible as it included other diseases (latent tuberculosis infection, cryptococcal meningitis, chronic hepatitis B, among others) and other index tests (NAAT, Xpert MTB/RIF assay, neutrophil CD64, among others); 159 records were non-eligible types of reports including reviews, recommendations, consensus, systematic review/meta-analysis, and abstracts; 70 records were of animal and cellular studies; and 46 records were case reports and case series. We then assessed 65 full-text articles in detail (Fig 1). Ultimately, 20 articles were selected for characteristic collection and data analysis (Tables 1 and 2) [28–47].

The final dataset of 20 articles comprised 1,978 participants (701 TBM patients and 1,277 non-TBM individuals), with an overall TBM prevalence of 35.44%. Fourteen (70%) articles were reported from countries recognized as ‘high burden’ by the WHO [28, 30–35, 37, 39, 41–43, 45, 46]. Thirteen publications (65%) were of prospective studies [28–31, 34, 36, 38, 39, 42–46]. All the studies used various composite reference standards. Four studies estimated unstimulated CSF IFN-γ levels with different methods (Luminex kits, ELISA, radioimmunoassay) and diagnostic thresholds (0.244–6.4 IU/mL) [30, 37, 42, 47], and one study tested unstimulated blood IFN-γ levels using Luminex kits assay with a cutoff of 0.62 IU/mL [31]. Twenty-three studies used IGRA (T-SPOT.TB and QFT-GIT) to estimate TBAg-stimulated IFN-γ levels using ELISPOT and ELISA methods, including eight studies that analyzed CSF samples.
and fifteen studies that analyzed blood samples. Diagnostic thresholds of the T-SPOT.TB differed widely from 5–46 spot-forming cells (SFCs) in CSF and 5–45 SFCs in blood, with six being the most used manufacturers’ recommended cutoff. According to the manufacturer’s recommendation, the cutoff value of QFT-GIT was 0.35 IU/mL in CSF and blood, while one study used 10 IU/mL in blood (Table 1). In total, 28 studies included 2,641 samples (896 TBM samples and 1,565 non-TBM samples) from blood and CSF. Diagnostic accuracy estimates of
### Table 1. Characteristics of the included articles.

| Author         | Year | Country      | TB-burden | Study design | TBM/non-TBM individuals (N) | Reference standard | Index test |
|----------------|------|--------------|-----------|--------------|-----------------------------|-------------------|------------|
| Luo Y          | 2021 | China        | High      | Prospective  | 76/98                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood) | Yes  |
| Luo Y          | 2021 | China        | High      | Prospective  | 39/66                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood) | Yes  |
| Kwon JS        | 2019 | Republic of Korea | Low | Prospective  | 10/45                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 14 SFCs (Blood)/13.5 SFCs (CSF) | Yes  |
| Manyelo CMa    | 2019 | South Africa | High      | Prospective  | 23/24                       | Composite IFN-γ Luminex kits 1.00 IU/ml (CSF) | No          |
| Manyelo CMb    | 2019 | South Africa | High      | Prospective  | 23/24                       | Composite IFN-γ Luminex kits 0.62 IU/ml (Blood) | No          |
| Di L           | 2018 | China        | High      | Retrospectively | 8/251                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood) | Yes  |
| Li XL          | 2017 | China        | High      | Retrospectively | 52/44                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 10 SFCs (CSF) | Yes  |
| Pan L          | 2017 | China        | High      | Prospective  | 53/37                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 24 SFCs (Blood)/20 SFCs (CSF) | Yes  |
| Lu T           | 2017 | China        | High      | Retrospectively | 43/85                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood) | Yes  |
| Park KH        | 2016 | Republic of Korea | Low | Prospective  | 49/186                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 45 SFCs (Blood)/12 SFCs (CSF) | Yes  |
| Lu D           | 2016 | China        | High      | un           | 30/39                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood) | Yes  |
| Lu D           | 2016 | China        | High      | un           | 30/39                       | Composite IFN-γ ELISA 0.81 IU/ml (CSF) | No          |
| El Azbaoui S   | 2016 | Morocco      | Low       | Prospective  | 12/28                       | Composite IGRA (QFT-GIT) ELISA 0.35 IU/ml (Blood) | Yes          |
| Qin L          | 2015 | China        | High      | Prospective  | 12/28                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 6 SFCs (Blood/CSF) | Yes  |
| Caliman-Sturdza OA | 2015 | Romania     | Low       | un           | 63/62                       | Composite IGRA (QFT-GIT) ELISA 0.35 IU/ml (Blood/CSF) | Yes          |
| Vidhate MR     | 2011 | India        | High      | un           | 24/16                       | Composite IGRA (QFT-GIT) ELISA 10 IU/ml (Blood) | Yes          |
| Patel VB       | 2011 | South Africa | High      | Prospective  | 37/15                       | Composite IFN-γ ELISA 0.244 IU/ml (CSF) | No          |
| Patel VB       | 2010 | South Africa | High      | Prospective  | 94/48                       | Composite IGRA (T-SPOT. TB) | ELISPOT     | 46 SFCs (CSF) | Yes  |
| Liao CH        | 2009 | Taiwan       | Low       | Prospective  | 6/14                        | Composite IGRA (T-SPOT. TB) | ELISPOT     | 10 SFCs (Blood) | Yes  |
| Chen X         | 2009 | China        | High      | Prospective  | 16/121                      | Composite IGRA (T-SPOT. TB) | ELISPOT     | 11 SFCs (Blood) | Yes  |

(Continued)

---

Tuberculosis-specific antigen stimulated and unstimulated interferon-γ for tuberculous meningitis diagnosis

PLOS ONE | https://doi.org/10.1371/journal.pone.0273834 | August 30, 2022 | 6/17
blood and CSF IGRA (T-SPOT.TB and QFT-GIT) and unstimulated IFN-γ-detecting TBM are shown in Table 2.

Quality of the eligible articles

According to the QUADAS-2 tool, we found a low risk of quality bias for the included articles (Fig 2). Patient selection bias was unclear for five articles (5/20, 25%), as investigators did not report consecutive selection for patient included criteria [33, 40, 44, 45, 47]. The unclear bias primarily resulted in the index test domain (7/20, 35%) [32, 33, 37, 38, 40, 41, 44] and reference standard domain (16/20, 70%) [28–33, 35–41, 44, 45, 47], as reviewers failed to judge study blinding by insufficient information. Flow and timing bias were unclear for seven articles (7/20, 35%), as investigators excluded intermediate results of IFN-γ and/or missing data of participants [29, 34, 36, 38, 40, 43, 46]. Five (5/20, 25%) studies additionally had unclear applicability concerns in the patient selection domain, as the main characteristics of TBM were unclear, in which these publications focused on extrapulmonary TB [32, 33, 38, 44, 45].

Diagnostic accuracy of blood IGRA

To differentiate TBM individuals from non-TBM controls, a total of 1,495 blood samples from 15 studies using IGRA were evaluated. The sensitivity ranged from 0.25 to 1.00, with a summary sensitivity of 0.73 (95% CI: 0.63–0.81; $I^2$: 74.70%) ($S$1 Fig). The specificity varied between 0.63 and 1.00, with a summary specificity of 0.83 (95% CI: 0.79–0.87; $I^2$: 66.68%) ($S$1 Fig). The summary PLR and NLR were 4.32 (95% CI: 3.42–5.46) and 0.33 (95% CI: 0.23–0.46), respectively. The summary DOR was 13.22 (95% CI: 8.22–21.25). The AUROC was 0.86 (95% CI: 0.83–0.89), suggesting that the diagnostic accuracy of blood IGRA was good. The HSROC curve of blood IGRA is shown in Fig 3.

We observed relatively high heterogeneity ($I^2$ = 74.70% for sensitivity) among the eligible studies. In the meta-regression and subgroup analyses, the different forms of blood TBAg stimulated IFN-γ (T-SPOT.TB and QFT-GIT) was not the cause of heterogeneity ($P$ = 0.46). The pooled sensitivity of blood T-SPOT.TB was higher when compared with QFT-GIT (0.75 vs. 0.64). The pooled specificity of T-SPOT.TB was lower when compared with QFT-GIT (0.82 vs. 0.88).

Diagnostic accuracy of CSF IGRA

Eight studies, comprising 694 CSF samples, were included in the IGRA group. The summary sensitivity and specificity were 0.77 (95% CI: 0.56–0.90; $I^2$: 87.76%) and 0.91 (95% CI: 0.85–
The summary PLR and NLR were 8.82 (95% CI: 4.97–15.63) and 0.25 (95% CI: 0.12–0.53), respectively. The summary DOR was 34.59 (95% CI: 12.25–97.64). The AUROC was 0.93 (95% CI: 0.91–0.95), suggesting that the diagnostic accuracy of CSF IGRA was good. The HSROC curve of CSF IGRA is shown in Fig 4.

High heterogeneity was observed between the included studies ($I^2 = 87.76\%$ sensitivity). In the meta-regression and subgroup analyses, the different forms of CSF TBAg stimulated IFN-γ (T-SPOT.TB and QFT-GIT) might not be the cause of heterogeneity ($P = 0.07$). The pooled sensitivity and specificity of CSF T-SPOT.TB were 0.75 and 0.88, respectively. In addition, the pooled sensitivity and specificity of CSF QFT-GIT were 0.81 and 0.98, respectively.

### Table 2. Diagnostic performance of IFN-γ in the individual studies.

| Author                | Year | Samples | Sensitivity% (95% CI) | Specificity% (95% CI) | TP    | FP    | FN    | TN    |
|-----------------------|------|---------|-----------------------|-----------------------|-------|-------|-------|-------|
| **Blood IGRA (T-SPOT.TB and QFT-GIT)** |      |         |                       |                       |       |       |       |       |
| Luo Y                 | 2021 | 76      | 85.53 (67.7–65.3)     | 91.63 (78.8–97.5)     | 65    | 18    | 11    | 80    |
| Luo Y                 | 2021 | 39      | 79.49 (61.1–84.2)     | 92.83 (62.0–81.7)     | 31    | 15    | 5     | 51    |
| Kwon JS               | 2019 | 10      | 50.0 (18.7–81.3)      | 77.8 (62.9–88.8)      | 5     | 10    | 5     | 35    |
| Di L                  | 2018 | 8       | 25                   | 92.83 (62.0–81.7)     | 2     | 18    | 6     | 233   |
| Pan L                 | 2017 | 53      | 90.6 (79.3–96.9)      | 75.7 (58.8–88.2)      | 48    | 9     | 5     | 28    |
| Lu T                  | 2017 | 43      | 72.1 (56.1–84.2)      | 72.9 (62.0–81.7)      | 31    | 23    | 12    | 62    |
| Park KH               | 2016 | 46      | 65 (50–79)            | 84 (78–90)            | 30    | 25    | 16    | 134   |
| Lu D                  | 2016 | 30      | 70 (54–86)            | 87 (73–96)            | 21    | 5     | 9     | 34    |
| Qin L                 | 2015 | 12      | 83 (52–98)            | 82 (63–94)            | 10    | 5     | 2     | 23    |
| Liao CH               | 2009 | 6       | 100                  | 71.4                  | 7     | 4     | 4     | 10    |
| Chen X                | 2009 | 16      | 62.5                 | 85.95                 | 10    | 17    | 6     | 104   |
| Thomas MM             | 2008 | 11      | 82 (48–98)           | 75 (35–97)            | 9     | 2     | 2     | 6     |
| El Azbaoui S          | 2016 | 10      | 80                   | 100                   | 8     | 0     | 2     | 28    |
| Caliman-Sturdza OA   | 2015 | 58      | 77.6                 | 87.9                  | 45    | 7     | 13    | 51    |
| Vidhate MR            | 2011 | 24      | 33.3                 | 62.5                  | 8     | 6     | 16    | 10    |
| **CSF IGRA (T-SPOT.TB and QFT-GIT)** |      |         |                       |                       |       |       |       |       |
| Kwon JS               | 2019 | 10      | 30.0 (6.7–65.3)       | 91.1 (78.8–97.5)      | 3     | 4     | 7     | 41    |
| Li XL                 | 2017 | 52      | 97.8 (87–99.9)        | 78 (63.7–88)          | 51    | 10    | 1     | 34    |
| Pan L                 | 2017 | 51      | 60.8 (46.1–74.2)      | 97.2 (85.5–99.9)      | 31    | 1     | 20    | 35    |
| Park KH               | 2016 | 38      | 66 (49–80)           | 90 (83–95)            | 25    | 11    | 13    | 98    |
| Qin L                 | 2015 | 12      | 92 (62–100)          | 93 (76–99)            | 11    | 2     | 1     | 26    |
| Patel VB              | 2010 | 92      | 52 (42–63)           | 83 (70–93)            | 48    | 8     | 44    | 40    |
| Thomas MM             | 2008 | 10      | 90 (56–100)          | 100 (59–100)          | 9     | 0     | 1     | 7     |
| Caliman-Sturdza OA   | 2015 | 56      | 80.4                 | 98.2                  | 45    | 1     | 11    | 55    |
| **Blood unstimulated IFN-γ** |      |         |                       |                       |       |       |       |       |
| Manyelo CMb           | 2019 | 23      | 87.0 (66.4–92.2)      | 20.8 (7.1–42.2)       | 20    | 19    | 3     | 5     |
| **CSF unstimulated IFN-γ** |      |         |                       |                       |       |       |       |       |
| Manyelo CMa           | 2019 | 23      | 91.3 (72.0–98.9)      | 91.7 (73.0–99.0)      | 21    | 2     | 2     | 22    |
| Lu D                  | 2016 | 30      | 83 (65–94)           | 85 (69–93)            | 25    | 6     | 5     | 33    |
| Patel VB              | 2011 | 37      | 92 (78–98)           | 100 (78–100)          | 34    | 0     | 3     | 15    |
| San Juan R            | 2006 | 20      | 70 (50–90)           | 95 (90–98)            | 14    | 2     | 6     | 35    |

Abbreviations: IFN-γ: interferon; IGRA: interferon-gamma release assay; QFT-GIT: QuantiFERON-TB Gold in-tube; TBM: tuberculous meningitis; CSF: cerebrospinal fluid; CI: Confidence interval; TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative

https://doi.org/10.1371/journal.pone.0273834.t002
Diagnostic accuracy of unstimulated blood and CSF IFN-γ

One study reported a low specificity (0.21) for unstimulated blood IFN-γ. Four studies, including 225 CSF samples, were performed using unstimulated IFN-γ. The summary sensitivity and specificity of 0.86 (95% CI: 0.76–0.92; $I^2$: 48.70%) and 0.92 (95% CI: 0.82–0.96; $I^2$: 31.75%), respectively (S3 Fig). The summary PLR and NLR were 10.27 (95% CI: 4.57–23.08) and 0.16 (95% CI: 0.09–0.27), respectively. The summary DOR was 65.26 (95% CI: 21.69–196.34). The AUROC was 0.95 (95% CI: 0.93–0.97), suggesting that the diagnostic accuracy of unstimulated CSF IFN-γ was excellent. The summary point was located near the preferred upper left corner of the HSROC curve, indicating that unstimulated CSF IFN-γ was a good discriminator (Fig 5).

Publication bias

Deeks’ funnel plots showed no statistically significant differences in blood IGRA ($P = 0.61$), CSF IGRA ($P = 0.84$), and unstimulated CSF IFN-γ ($P = 0.12$). Therefore, there was no publication bias in this study.

Discussion

Our results suggest that blood IGRA demonstrates good diagnostic potential in TBM diagnosis with an AUROC of 0.86. CSF IGRA also showed good diagnostic performance for TBM diagnosis with an AUROC of 0.93. Further, our analysis revealed that the different types of IGRA was not the cause of heterogeneity. In the case of active TB, $M. tuberculosis$-specific effector T cells could be recruited to the infection site, and then IGRA was used to detect TBAg-stimulated IFN-γ at the infection site (for example, using CSF), which could present a higher specificity of TB diagnosis compared with blood IGRA [20, 32, 48]. Our study revealed a higher diagnostic specificity (0.91) for CSF IGRA; however, the specificity of blood IGRA was of 0.83. Our study also showed a slightly higher sensitivity (0.77) of CSF IGRA according to data from eight studies, whereas the sensitivity of blood IGRA was 0.73 based on 15 studies. We assume that the possible reason for lower sensitivity is the protective effect of the blood-brain barrier [32].

Using eight original articles, Yu et al. (2016) performed a meta-analysis of blood and CSF IGRA for distinguishing between TBM and non-TBM individuals [19], in which blood IGRA had a pooled sensitivity of 0.78 and specificity of 0.61, whereas CSF IGRA had a pooled
Fig 3. Hierarchical summary receiver operating characteristic (HSROC) plot to summarize diagnostic accuracy for blood IGRA in diagnosing tuberculous meningitis (blue curve). Summary estimate of diagnostic accuracy is indicated by the red square.

https://doi.org/10.1371/journal.pone.0273834.g003
Fig 4. Hierarchical summary receiver operating characteristic (HSROC) plot to summarize diagnostic accuracy for CSF IGRA in diagnosing tuberculous meningitis.

https://doi.org/10.1371/journal.pone.0273834.g004
Fig 5. Hierarchical summary receiver operating characteristic (HSROC) plot to summarize diagnostic accuracy for unstimulated CSF IFN-\(\gamma\) in diagnosing tuberculous meningitis.

https://doi.org/10.1371/journal.pone.0273834.g005
sensitivity of 0.77 and specificity of 0.83. However, this analysis included one article that combined other CNS TB (such as intracranial tuberculoma) patient data into the TBM data [20]. Moreover, three other articles had overlapping datasets [21, 48, 49]. Therefore, a 2016 new research including the largest participant samples was selected for our study. In addition, the remaining four original articles from the meta-analysis by Yu et al. were selected. We have improved the reliability and stability of the diagnostic performance of IGRA for detecting TBM by analyzing 14 additional publications. Furthermore, we analyzed the unstimulated IFN-γ.

In 2020, Luo et al. included 27 articles and showed that, for TBM diagnosis, the pooled sensitivity and specificity of blood T-SPOT.TB were 0.78 and 0.68, and the pooled sensitivity and specificity of CSF T-SPOT.TB were 0.76 and 0.88 [50]. However, this research also included intracranial tuberculoma patient data for one article [20] and overlapping datasets in four articles [21, 36, 48, 49], causing unreliable pooled results. Besides, 14 eligible articles are in Chinese, which might lead to biased results. Our study included a newest article with the largest participant samples [36], excluding overlapping datasets [21, 48, 49] and admixture of other brain tuberculosis [20], which conducted more truthful results. Furthermore, we included other 11 original articles and analyzed the performance of QFT-GIT and unstimulated IFN-γ for TBM. In 2021, Lan et al. included 26 publications, and found blood IGRA had a pooled sensitivity of 0.81 and specificity of 0.76 for TBM, and CSF IGRA had a pooled sensitivity of 0.81 and specificity of 0.89 [51]. This meta-analysis had the same problems as Luo et al., in which three included articles had overlapping datasets [21, 36, 49] and 17 were in Chinese. Our study excluded overlapping datasets [21, 49] and Chinese publications, which could increase the reliability of pooled results. Besides, we included other 12 original articles and estimated the detective value of unstimulated IFN-γ.

A systematic review published by Aggarwal et al. in 2021, comprising 7,153 patients, showed that the IFN-γ of unstimulated pleural fluid provided excellent accuracy for diagnosing tuberculous pleural effusion (sensitivity: 0.93, specificity: 0.96) [52]. To date, the diagnostic performance of unstimulated CSF IFN-γ for TBM remained unclear. In our study, unstimulated CSF IFN-γ had a relatively high summary sensitivity (0.86) and specificity (0.92). The AUROC was of 0.95, suggesting that the diagnostic accuracy of unstimulated CSF IFN-γ was excellent. In 2017, Pormohammad et al. performed a systematic review of CSF ADA, indicating that CSF ADA had a relatively high accuracy for TBM diagnosis (sensitivity, 0.89; specificity, 0.91; AUROC, 0.96) [53]. The diagnostic accuracy estimates of the unstimulated CSF IFN-γ in the current study are similar to those reported for CSF ADA by Pormohammad et al. Overall, this suggests that unstimulated CSF IFN-γ may be as useful as currently common diagnostic biomarkers, such as ADA, for TBM.

Our meta-analysis had several limitations. First, we could not rule out a misclassification bias because all studies used composite criteria for diagnosing TBM. Second, the different forms of TBAg-stimulated IFN-γ were not the significant source of heterogeneity, however, we did not evaluate other possible factors (such as patient age, HIV-coinfection condition). Furthermore, for TBAg-unstimulated IFN-γ, we did not analyze potential factors for heterogeneity, e.g., clinical types of non-TBM participants, which might influence the interpretability of the pooled results. Third, some studies derived diagnostic thresholds of stimulated IFN-γ in a post-hoc fashion by optimizing the trade-off between specificity and sensitivity, rather than using a manufacturer recommended cutoff, which could be more clinically appropriate for confirmation or exclusion of a TBM diagnosis. Additionally, there was no publication bias in this study; however, we only included studies published in English journals; thus, a concern for publication bias could not be excluded. In clinic, a large CSF sample was needed for the stimulation of IFN-γ among TBM patients with few lymphocytes in the CSF, which is a
challenge. Moreover, different age may affect the diagnosis of TBM. In further study, for TBM detection, it is better to explore the pediatric cases and adult patients separately.

In conclusion, this systematic review and meta-analysis shows that blood and CSF IGRA are good assays for differentiating TBM from non-TBM individuals, and unstimulated CSF IFN-γ is an auxiliary excellent marker for detecting TBM. Further large-scale, multi-center, prospective studies are warranted to support our findings, especially the findings on unstimulated CSF IFN-γ.

Supporting information

S1 Checklist. PRISMA 2020 checklist.

S1 Fig. The pooled sensitivity and specificity of blood IGRA for diagnosing tuberculous meningitis.

S2 Fig. The pooled sensitivity and specificity of CSF IGRA for diagnosing tuberculous meningitis.

S3 Fig. The pooled sensitivity and specificity of unstimulated CSF IFN-γ for diagnosing tuberculous meningitis.

Author Contributions

Conceptualization: Fangyu Shi, Xia Qiu, Mingjing Yu, Yan Huang.

Data curation: Fangyu Shi, Xia Qiu, Mingjing Yu, Yan Huang.

Funding acquisition: Yan Huang.

Methodology: Fangyu Shi, Xia Qiu, Yan Huang.

Resources: Yan Huang.

Software: Fangyu Shi, Xia Qiu, Mingjing Yu, Yan Huang.

Supervision: Fangyu Shi, Xia Qiu, Mingjing Yu, Yan Huang.

Validation: Fangyu Shi, Xia Qiu, Mingjing Yu.

Visualization: Fangyu Shi, Xia Qiu, Mingjing Yu, Yan Huang.

Writing – original draft: Fangyu Shi, Xia Qiu, Mingjing Yu.

Writing – review & editing: Fangyu Shi, Xia Qiu, Yan Huang.

References

1. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
2. Seddon JA, Tugumie L, Solomons R, Prasad K, Bahr NC. Tuberculous Meningitis International Research Consortium. Tuberculous Meningitis International Research Consortium. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019; 4:167. https://doi.org/10.12688/wellcomeopenres.15535.1 PMID: 32118118
3. Manyelo CM, Solomons RS, Walzl G, Chegou NN. Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches. J Clin Microbiol. 2021; 59: e01771–20. https://doi.org/10.1128/JCM.01771-20 PMID: 33087432

4. Wilkinson RJ, Rohlwink U, Misra UK, Crevel RV, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017; 13:581–598. https://doi.org/10.1038/nrneurol.2017.120 PMID: 28884751

5. Ahlawat S, Chaudhary R, Dangi M, Bala K, Singh M, Chhillar AK. Advances in tuberculous meningitis diagnosis. Expert Rev Mol Diagn. 2020; 20:1229–1241. https://doi.org/10.1080/14737159.2020.1858805 PMID: 33295249

6. Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010; 10:803–12. https://doi.org/10.1016/S1473-3099(10)70138-9 PMID: 20822958

7. Kaviyi JE, Ravikumar R. Diagnosis of tuberculous meningitis: Current scenario from a Tertiary Neurocare Centre in India. Indian J Tuberc. 2017; 64: 183–188. https://doi.org/10.1016/j.ijtb.2017.01.005 PMID: 28709486

8. Bahr NC, Meintjes G, Boulware DR. Inadequate diagnostics: the case to move beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis. J Med Microbiol. 2019; 68:755–760. https://doi.org/10.1099/jmm.0.009975 PMID: 30994435

9. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, et al. GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but Not the Last. Clin Infect Dis. 2016; 62:1133–1135. https://doi.org/10.1093/cid/ciw083 PMID: 26966284

10. Pormohammad A, Nasiri MJ, McHugh TD, Raihi SM, Bahr NC. A systematic review and meta-analysis of the diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis. J Clin Microbiol. 2019; 57: e01113–18. https://doi.org/10.1128/JCM.01113-18 PMID: 30944198

11. Solomon RS, van Elsland SL, Visser DH, Hoek KG, Marais BJ, Schoeman JF, et al. Commercial nucleic acid amplification tests in tuberculous meningitis—a meta-analysis. Diagn Microbiol Infect Dis. 2014; 78:398–403. https://doi.org/10.1016/j.diagmicrobio.2014.01.002 PMID: 24503504

12. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, et al. Improved diagnostic sensitivity for TB meningitis with Xpert MTB/Rif of centrifuged CSF: a prospective study. Int J Tuberc Lung Dis. 2015; 19:1209–1215. https://doi.org/10.5588/ijtld.15.0253 PMID: 26459535

13. Botha H, Ackerman C, Candy S, Carr JA, Griffith Richards S, Bateman KJ. Reliability and diagnostic performance of CT imaging criteria in the diagnosis of tuberculous meningitis. PLoS One. 2012; 7: e38982. https://doi.org/10.1371/journal.pone.0038982 PMID: 22768055

14. Corral I, Quereda C, Navas E, Martín-Dávila P, Pérez-Elias MJ, Casado JL, et al. Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis. Eur J Clin Microbiol Infect Dis. 2004; 23:471–476. https://doi.org/10.1007/s10096-004-1110-z PMID: 15141333

15. Almolda B, González B, Castellano B. Are microglial cells the regulators of lymphocyte responses in the CNS? Front Cell Neurosci. 2015; 9:440–440. https://doi.org/10.3389/fncel.2015.00440 PMID: 26635525

16. Rock RB, Hu S, Gekker G, Sheng WS, May B, Kapur V, et al. Mycobacterium tuberculosis–induced cytokine and chemokine expression by human microglia and astrocytes: effects of dexamethasone. J Infect Dis. 2005; 192:2054–2058. https://doi.org/10.1086/498165 PMID: 16288367

17. Nagesh Babu G, Kumar A, Kalita J, Misra UK. Proinflammatory cytokine levels in the serum and cerebrospinal fluid of tuberculous meningitis patients. Neurosci Lett. 2008; 436:48–51. https://doi.org/10.1016/j.neulet.2008.02.060 PMID: 18359564

18. Misra UK, Kalita J, Srivastava R, Nair PP, Mishra MK, Basu A. A study of cytokines in tuberculous meningitis: clinical and MRI correlation. Neurosci Lett. 2010; 485:6–8. https://doi.org/10.1016/j.neulet.2010.07.029 PMID: 20691761

19. Yu J, Wang ZJ, Chen LH, Li HH. Diagnostic accuracy of interferon-gamma release assays for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis. 2016; 20:494–9. https://doi.org/10.5588/ijtld.15.0600 PMID: 26970159

20. Kim SH, Chu K, Choi SJ, Song KH, Kim HB, Kim NJ, et al. Diagnosis of central nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Vaccine Immunol. 2008; 15:1356–62. https://doi.org/10.1128/CVI.00400-08 PMID: 18632925

21. Cho OH, Park KH, Kim SM, Park SJ, Moon SM, Chong YP, et al. Diagnostic performance of T-SPOT. TB for extrapulmonary tuberculosis according to the site of infection. J Infect. 2011; 63:362–9. https://doi.org/10.1016/j.jinf.2011.06.010 PMID: 21781986

22. McLnnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies:
the PRISMA-DTA statement. JAMA. 2018; 319:388–396. https://doi.org/10.1001/jama.2017.19163 PMID: 29362800

23. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009 PMID: 22007046

24. Qiu X, Wang H, Tang Y, Su X, Ge L, Qu Y, et al. Is interleukin-2 a optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis. Ann Med. 2020; 52:376–385. https://doi.org/10.1080/07853890.2020.1800073 PMID: 32706045

25. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001; 20:2865–84. https://doi.org/10.1002/sim.942 PMID: 11568945

26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120

27. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58:882–93. https://doi.org/10.1016/j.jclinepi.2005.01.016 PMID: 16085191

28. Luo Y, Xue Y, Lin Q, Mao L, Tang G, Song H, et al. Diagnostic Model for Discrimination Between Tuberculous Meningitis and Bacterial Meningitis. Front Immunol. 2021; 12:731876. https://doi.org/10.3389/fimmu.2021.731876 PMID: 34867952

29. Kwon JS, Park JH, Kim JY, Cha HH, Kim MJ, Chong YP, et al. Diagnostic usefulness of cytokine and chemokine levels in the cerebrospinal fluid of patients with suspected tuberculous meningitis. Am J Trop Med Hyg. 2019; 101:343–9. https://doi.org/10.4269/ajtmh.18-0947 PMID: 31264559

30. Manyelo CM, Solomons RS, Snyders CI, Manngo PM, Mutavhatsindi H, Kriel B, et al. Application of Cerebrospinal Fluid Host Protein Biosignatures in the Diagnosis of Tuberculous Meningitis in Children from a High Burden Setting. Mediators Inflamm. 2019; 2019:7582948. https://doi.org/10.1155/2019/7582948 PMID: 31148946

31. Manyelo CM, Solomons RS, Snyders CI, Mutavhatsindi H, Manngo PM, Stanley K, et al. Potential of Host Serum Protein Biomarkers in the Diagnosis of Tuberculous Meningitis in Children. Front Pediatr. 2019; 7:376. https://doi.org/10.3389/fped.2019.00376 PMID: 31612118

32. Di L, Li Y. The risk factor of false-negative and false-positive for T-SPOT.TB in active tuberculosis. J Clin Lab Anal. 2018; 32: e22273. https://doi.org/10.1002/jcla.22273 PMID: 28594104

33. Li XL, Xie N, Wang SW, Wu QH, Ma Y, Shu W, et al. Diagnostic value of cerebrospinal fluid T-SPOT.TB for tuberculous meningitis in China. Biomed Environ Sci. 2017; 30:681–4. https://doi.org/10.3967/bes2017.091 PMID: 29081344

34. Pan L, Liu F, Zhang J, Yang X, Zheng S, Li J, et al. Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in Children. Biomed Res Int. 2017; 2017:8198505. https://doi.org/10.1155/2017/8198505 PMID: 28316991

35. Lu T, Lin X, Shu Y, Tian Q, Dai Y. Positive interferon-gamma release assay results are correlated with paradoxical reaction in tuberculous meningitis. Int J Clin Exp Med. 2017; 10:13669–13677.

36. Park KH, Lee MS, Kim SM, Park SJ, Chong YP, Lee SO, et al. Diagnostic usefulness of T-cell based assays for tuberculous meningitis in HIV-uninfected patients. J Infect. 2016; 72:486–97. https://doi.org/10.1093/ije/dyv125 PMID: 28488210

37. Qiu X, Wang H, Tang Y, Su X, Ge L, Qu Y, et al. Is interleukin-2 a optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis. Ann Med. 2020; 52:376–385. https://doi.org/10.1080/07853890.2020.1800073 PMID: 32706045

38. Luo Y, Xue Y, Lin Q, Mao L, Tang G, Song H, et al. Diagnostic Model for Discrimination Between Tuberculous Meningitis and Bacterial Meningitis. Front Immunol. 2021; 12:731876. https://doi.org/10.3389/fimmu.2021.731876 PMID: 34867952

39. Manyelo CM, Solomons RS, Snyders CI, Manngo PM, Mutavhatsindi H, Kriel B, et al. Application of Cerebrospinal Fluid Host Protein Biosignatures in the Diagnosis of Tuberculous Meningitis in Children from a High Burden Setting. Mediators Inflamm. 2019; 2019:7582948. https://doi.org/10.1155/2019/7582948 PMID: 31148946

40. Pan L, Liu F, Zhang J, Yang X, Zheng S, Li J, et al. Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in Children. Biomed Res Int. 2017; 2017:8198505. https://doi.org/10.1155/2017/8198505 PMID: 28316991

41. Lu T, Lin X, Shu Y, Tian Q, Dai Y. Positive interferon-gamma release assay results are correlated with paradoxical reaction in tuberculous meningitis. Int J Clin Exp Med. 2017; 10:13669–13677.

42. Park KH, Lee MS, Kim SM, Park SJ, Chong YP, Lee SO, et al. Diagnostic usefulness of T-cell based assays for tuberculous meningitis in HIV-uninfected patients. J Infect. 2016; 72:486–97. https://doi.org/10.1093/ije/dyv125 PMID: 28488210
43. Patel VB, Singh R, Connolly C, Coovadia Y, Peer AKC, Parag P, et al. Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Am J Respir Crit Care Med. 2010; 182:569–77. https://doi.org/10.1164/rccm.200912-1931OC PMID: 20442433

44. Liao CH, Chou CH, Lai C, Huang YT, Tan CK, Hsu HL, et al. Diagnostic performance of an enzyme-linked immunospot assay for interferon-gamma in extrapulmonary tuberculosis varies between different sites of disease. J Infect. 2009; 59:402–8. https://doi.org/10.1016/j.jinf.2009.10.001 PMID: 19819258

45. Chen X, Yang Q, Zhang M, Graner M, Zhu X, Larmonier N, et al. Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol. 2009; 16:879–84. https://doi.org/10.1128/CVI.00044-09 PMID: 19339489

46. Thomas MM, Hinks TSC, Raghuraman S, Ramalingam N, Ernst M, Nau R, et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int J Tuberc Lung Dis. 2008; 12:651–7. PMID: 18492332

47. Juan RS, Sánchez-Suárez C, Rebollo MJ, Folgueira D, Palenque E, Ortuño B, et al. Interferon gamma quantification in cerebrospinal fluid compared with PCR for the diagnosis of tuberculous meningitis. J Neurol. 2006; 253:1323–30. https://doi.org/10.1007/s00415-006-0215-y PMID: 16786212

48. Kim SH, Cho OH, Park SJ, Lee EM, Kim MN, Lee SO, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis. 2010; 50:1349–1358. https://doi.org/10.1086/652142 PMID: 20380567

49. Park KH, Cho OH, Lee EM, Lee SO, Choi SH, Kim YS, et al. T-cell-based assays on cerebrospinal fluid and PBMCs for rapid diagnosis of TB meningitis in non-HIV patients. Eur Respir J. 2012; 39:768–770. https://doi.org/10.1183/09031936.00098111 PMID: 22379149

50. Luo Y, Xue Y, Guo X, Lin Q, Mao L, Tang G, et al. Diagnostic Accuracy of T-SPOT.TB Assay for Tuberculous Meningitis: An Updated Meta-Analysis. Front Neurol. 2020; 11: 866. https://doi.org/10.3389/fneur.2020.00866 PMID: 33013621

51. Lan Y, Chen W, Yan Q, Liu W. Interferon-γ release assays for tuberculous meningitis diagnosis: a meta-analysis. Arch Med Sci. 2021; 17: 1241–1250. https://doi.org/10.5114/ams.2019.86994 PMID: 34522253

52. Aggarwal AN, Agarwal R, Dhooaria S, Prasad KT, Sehgal IS, Muthu V. Unstimulated Pleural Fluid Interferon Gamma for Diagnosis of Tuberculous Pleural Effusion: a Systematic Review and Meta-analysis. J Clin Microbiol. 2021; 59: e02112–20. https://doi.org/10.1128/JCM.02112-20 PMID: 33206475

53. Pormohammad A, Riahi SM, Nasiri MJ, Fallah F, Aghazadeh M, Doustdar F, et al. Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: A systematic review and meta-analysis. J Infect. 2017; 74:545–554. https://doi.org/10.1016/j.jinf.2017.02.012 PMID: 28366687